Table 2

Participant demographics

Demographic variableInsomnia:
mean (M), SD and/or no reporting		No insomnia:
mean (M), SD and/or no reporting		Significance test for group differences
AgeM=42.70, SD=16.30 (range=23–67 years)M=48.00, SD=15.58 (range=29–73 years)t(18)=0.74, p=0.47
Sex9 female, 1 male2 female, 8 maleFisher’s exact p=0.002
Race/ethnicity10 white non-Hispanic10 white non-HispanicFisher’s exact p=1.0
IBD type and location7 Crohn’s disease
Location
3 ileal only
2 ileocolonic
1 colonic only
1 upper tract, colonic
Phenotype
3 inflammatory
3 stricturing
1 penetrating
Perianal Involvement
3 yes
4 no
3 ulcerative colitis
3 left sided disease		5 Crohn’s disease
3 ileal only
1 ileocolonic
1 colonic only
Phenotype
1 inflammatory
3 stricturing
1 penetrating
Perianal Involvement
2 yes
3 no
5 ulcerative colitis
3 left sided
2 extensive colitis		Fisher’s exact for Crohn’s vs UC p=0.65
Years since IBD diagnosisM=14.50, SD=12.87 (range=1–44 years)M=11.80, SD=9.39 (range=2–30 years)t(18)=-.56, p=0.58
IBD medications*9 taking:
3 infliximab alone
2 vedolizumab alone
1 ustekinumab alone
1 ustekinumab+prednisone
1 adalimumab +prednisone
1 mesalamine alone		10 taking:
2 adalimumab alone
1 adalimumab +azathioprine
1 infliximab alone alone
1 infliximab+prednisone
1 ustekinumab+prednisone
1 vedolizumab alone
1 mesalamine alone
1 mesalamine +methotrexate
1 sulfasalazine alone		Fisher’s exact p=1.0
Psychiatric medications (including sleep medications and hypnotics)*3 taking:
2 antidepressants
1 antidepressant, anticonvulsant and atypical antipsychotic		0 takingFisher’s exact p=0.21
Disease status (remission vs active) based on PRO-34 in remission
6 active disease		5 in remission
5 active disease		X2 (1, N=20)=0.20, p=0.65

  • Bolded values are significant though should be interpreted with caution given our small sample size.

  • *Dose did not change over the course of the trial.

  • IBD, inflammatory bowel disease; PRO-3, patient-reported outcome-3; UC, ulcerative colitis.